[18F]RO948 Tau PET in early and late onset Alzheimer’s disease: associations with plasma p-tau 217, atrophy and cognition

Le résumé fourni par la source

Abstract Purpose The aim of this study was to compare regional brain tau extent across the disease spectrum in early- and late-onset Alzheimer’s disease using the second-generation tau PET tracer [ 18 F]RO948, and to investigate the relationship between PET-derived patterns, plasma p-tau217, brain atrophy, and cognition. Methods We examined 57 participants: 39 patients from the Cognitive Assessment Unit at Karolinska University Hospital (Stockholm/Sweden)—diagnosed as MCI Aβ– ( n = 10), MCI Aβ + ( n = 16; 8 EO and 6 LO), and AD ( n = 13; 5 EOAD and 8 LOAD)—and 18 cognitively normal controls. All participants underwent [ 18 F]RO948 tau-PET, structural MRI, cognitive testing, and plasma p-tau217 analysis. Results Both EO and LO MCI (Aß +) showed higher [ 18 F]RO948 binding in amygdala, entorhinal cortex, hippocampus ( p < 0.001) and extending to inferior temporal regions ( p < 0.01) compared to controls, with some MCI-EO cases already showing advanced neocortical tau burden. At the AD stage, EOAD patients showed greater neocortical tau extent in temporo-parietal and frontal cortices than LOAD. P‑tau217 positively correlated with [ 18 F]RO948 in amygdala, entorhinal cortex, hippocampus (rho = 0.81) followed by temporal (rho = 0.71), and parietal cortices (rho = 0.56, all p < 0.001). The Tau‑PET/p-tau217 association was different between EOAD and LOAD with greater differences in parietal cortices. Tau‑PET also showed stronger region‑specific associations with cognitive impairment than p‑tau217, especially in EOAD. Conclusions [ 18 F]RO948-PET captured interindividual heterogeneity in tau accumulation that was not reflected by plasma p-tau217. This dissociation was particularly evident in neocortical regions, where LOAD showed elevated plasma p-tau217 levels despite low tau PET binding. These findings highlight the value of tau-PET as a sensitive biomarker for detecting early disease heterogeneity, assessing disease severity, and improving patient stratification for disease-modifying treatments.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.